JY
CRVS icon

Jeff Yass’s Corvus Pharmaceuticals CRVS Stock Holding History

Jeff Yass’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Buy
190,641
+152,005
+393% +$2.11M ﹤0.01% 5739
2026
Q1 		$565K Sell
38,636
-23,118
-37% -$369K ﹤0.01% 9352
2025
Q4 		$476K Buy
+61,754
New +$487K ﹤0.01% 8907
2025
Q3 		– Sell
-67,816
Closed -$347K – 12602
2025
Q2 		$271K Sell
67,816
-883,527
-93% -$3.21M ﹤0.01% 10574
2025
Q1 		$3.03M Sell
951,343
-63,740
-6% -$300K ﹤0.01% 4632
2024
Q4 		$5.43M Buy
1,015,083
+796,121
+364% +$5.94M ﹤0.01% 3465
2024
Q3 		$1.16M Buy
218,962
+193,312
+754% +$694K ﹤0.01% 6459
2024
Q2 		$46.7K Sell
25,650
-79,376
-76% -$148K ﹤0.01% 11438
2024
Q1 		$187K Sell
105,026
-115,270
-52% -$241K ﹤0.01% 10670
2023
Q4 		$388K Buy
220,296
+92,328
+72% +$135K ﹤0.01% 9261
2023
Q3 		$187K Sell
127,968
-67,284
-34% -$142K ﹤0.01% 10310
2023
Q2 		$447K Buy
195,252
+184,809
+1,770% +$384K ﹤0.01% 8574
2023
Q1 		$9.5K Buy
+10,443
New +$8.15K ﹤0.01% 12218
2022
Q2 		– Sell
-48,283
Closed -$59.2K – 13023
2022
Q1 		$79K Sell
48,283
-27,435
-36% -$50.2K ﹤0.01% 12061
2021
Q4 		$182K Sell
75,718
-12,579
-14% -$48.8K ﹤0.01% 11558
2021
Q3 		$427K Buy
88,297
+52,591
+147% +$156K ﹤0.01% 9783
2021
Q2 		$95K Sell
35,706
-55,532
-61% -$153K ﹤0.01% 12116
2021
Q1 		$281K Buy
91,238
+75,557
+482% +$273K ﹤0.01% 10752
2020
Q4 		$56K Buy
+15,681
New +$63.1K ﹤0.01% 10716
2020
Q2 		– Sell
-117,606
Closed -$248K – 10209
2020
Q1 		$248K Buy
117,606
+49,700
+73% +$202K ﹤0.01% 8324
2019
Q4 		$369K Buy
+67,906
New +$238K ﹤0.01% 7590

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jeff Yass's CRVS Position: Q2 2026 in Review

Jeff Yass increased its Corvus Pharmaceuticals (CRVS) stake by 393% in Q2 2026, buying an estimated $2.11M and bringing the position to 190,641 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #5739.

Jeff Yass first reported a position in CRVS in Q4 2019 and has held it in 21 quarters since. The position peaked at $5.43M in Q4 2024. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Jeff Yass held 190,641 shares of Corvus Pharmaceuticals worth $2.85M as of Q2 2026.
  • Jeff Yass bought 152,005 Corvus Pharmaceuticals shares in Q2 2026, an estimated $2.11M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5739 holding.
  • Jeff Yass first reported a position in Corvus Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Corvus Pharmaceuticals position peaked at $5.43M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.